Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Landscape of Prostate Tumour Methylation.

Cancer discovery·2026
Same author

European Study of Prostate Cancer Screening - 23-Year Follow-up.

The New England journal of medicine·2026
Same author

How "Floor Bias" in Gleason Grading Affects Prostate Cancer Management.

The Journal of urology·2026
Same author

Screening for Prostate Cancer with a Polygenic Risk Score.

The New England journal of medicine·2025
Same author

Investigating the Usage of Abiraterone in African American Men with Metastatic Prostate Cancer.

Journal of racial and ethnic health disparities·2025
Same author

Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening: Erratum.

The Journal of urology·2025
Same journal

On the Memoryless Property in Markov Models for NMIBC Cost-Effectiveness Analysis.

The Journal of urology·2026
Same journal

Multi-institutional Assessment of Performance Metrics for MRI-targeted Transperineal Prostate Biopsy.

The Journal of urology·2026
Same journal

Urinary Supersaturation in a Randomized Trial among Individuals with Recurrent Nephrolithiasis comparing Empiric versus Selective Preventive Therapy: The URINE Trial.

The Journal of urology·2026
Same journal

The FDA Should Allow More BCG Strains into the US Market: How Recent Landmark Trials Expose a Regulatory Paradox.

The Journal of urology·2026
Same journal

Let's Shift the Focus from Death to Life after Fournier's Gangrene.

The Journal of urology·2026
Same journal

Endourology and Nephrolithiasis.

The Journal of urology·2026
See all related articles

Related Experiment Video

Updated: Jun 23, 2026

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

17.0K

Joint Biochemical and Genetic Prostate Cancer Risk Stratification.

Nicole Zeltser1,2, Roni Haas1,2, Christine Ibilibor3

  • 1Department of Human Genetics, University of California, Los Angeles, California.

The Journal of Urology
|November 21, 2025
PubMed
Summary
This summary is machine-generated.

Polygenic hazard scores can improve prostate cancer (PC) screening for men with elevated PSA levels. These genetic scores help identify individuals at higher risk for clinically significant PC, refining current screening strategies.

Keywords:
PSApolygenic hazard scorepolygenic riskprospective studiesprostatic neoplasmsrisk assessment

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.7K
Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking
07:34

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking

Published on: November 17, 2023

1.1K

Related Experiment Videos

Last Updated: Jun 23, 2026

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

17.0K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.7K
Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking
07:34

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking

Published on: November 17, 2023

1.1K

Area of Science:

  • Oncology
  • Genetics
  • Preventive Medicine

Background:

  • Overdiagnosis of prostate cancer (PC) is common due to frequent PSA testing.
  • Men with baseline PSA ≥ 1 ng/mL require advanced diagnostic approaches for clinically significant disease.
  • Germline variants may enhance PC screening recommendations for at-risk individuals.

Purpose of the Study:

  • To investigate if common germline variants can improve screening recommendations for men with baseline PSA ≥ 1 ng/mL.
  • To assess the utility of polygenic hazard scores (PHS) in stratifying PC risk.
  • To evaluate the predictive performance of PHS290 combined with clinical covariates.

Main Methods:

  • Computed polygenic hazard scores for PC diagnosis (PHS290) in a cohort of 310 men with PSA ≥ 1 ng/mL.
  • Utilized regression models to predict PC clinical risk groups incorporating PHS290 and clinical covariates.
  • Compared PHS290 model performance against an existing 5-year risk calculator.

Main Results:

  • PHS290 successfully stratified individuals with PSA ≥ 1 ng/mL into distinct risk groups.
  • PHS290 identified men with intermediate-risk and high-risk PC.
  • Incorporating PHS290 improved predictions for time to intermediate- and high-risk PC compared to the existing calculator.

Conclusions:

  • Genetic scores, like PHS290, show potential for advancing PC screening guidance.
  • Molecular biomarkers can enhance risk stratification in tiered screening strategies.
  • Further validation in large cohorts is warranted for PC risk stratification using genetic scores.